Following a resubmission, the Scottish Medicines Consortium (SMC) has published advice on the use of agomelatine (Valdoxan®) within NHS Scotland, stating that it is not recommended for use for the treatment of major depressive episodes in adults.

The drug advice (see link below) notes that when used in a flexible dosing schedule, agomelatine significantly reduced the symptoms of depression and increased the number of patients who responded to treatment compared with placebo. There are however no comparative data from clinical studies with existing second line antidepressants using depression as the primary outcome, and the manufacturer did not present a sufficiently robust economic analysis to gain acceptance by the SMC.